Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny

• click to rate

  Posted by Two Blokes Jun 25 - Filed in Stock - 3 views
  
  The Food and Drug Administration (FDA) on Tuesday said it is investigating the risk of acute liver failure with serious outcomes, including hospitalization and death, following Sarepta Therapeutics, Inc.'s SRPT Elevidys treatment and evaluating the need for further regulatory action.